Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
University of Chicago
University of Chicago
University of Chicago
BeOne Medicines
Dana-Farber Cancer Institute
Eli Lilly and Company
Alliance for Clinical Trials in Oncology
University of Wisconsin, Madison
Massachusetts General Hospital
Incyte Corporation
Novartis
Fred Hutchinson Cancer Center
National Institutes of Health Clinical Center (CC)
Sanofi
Hoffmann-La Roche
Gilead Sciences
National Cancer Institute (NCI)
University of Washington
Incyte Corporation
BeiGene
City of Hope Medical Center
City of Hope Medical Center
Universität des Saarlandes
Incyte Corporation
Insel Gruppe AG, University Hospital Bern
University of Washington
Autolus Limited
International Extranodal Lymphoma Study Group (IELSG)
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
Ohio State University Comprehensive Cancer Center
University of Miami
BeiGene
Mayo Clinic
Ohio State University Comprehensive Cancer Center
Vanderbilt-Ingram Cancer Center
Gamida Cell ltd
National Cancer Institute (NCI)
Juno Therapeutics, a Subsidiary of Celgene
Ipsen
Antengene Corporation
Case Comprehensive Cancer Center
Janssen Research & Development, LLC
Janssen Research & Development, LLC
ADC Therapeutics S.A.
M.D. Anderson Cancer Center
Denovo Biopharma LLC
Mayo Clinic
Celgene
Acerta Pharma BV
Oncternal Therapeutics, Inc